Clinical Trial: NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07680699) titled 'NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma' on June 26.

Brief Summary: This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma.

Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study.

The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice.

No treatment...